Pathstone Family Office’s Novo Nordisk NVO Stock Holding History

Pathstone Family Office’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$4.67M	Buy	51,058 +11,320	+28%	+$997K	0.04%	286
2023 Q2	$3.26M	Sell	39,738 -4,120	-9%	-$337K	0.05%	230
2023 Q1	$3.51M	Sell	43,858 -65,586	-60%	-$4.65M	0.06%	191
2022 Q4	$6.54M	Sell	109,444 -7,212	-6%	-$423K	0.06%	234
2022 Q3	$5.86M	Buy	116,656 +77,252	+196%	+$4.14M	0.05%	210
2022 Q2	$2.2M	Buy	39,404 +7,574	+24%	+$420K	0.05%	199
2022 Q1	$1.81M	Buy	31,830 +2,334	+8%	+$120K	0.04%	189
2021 Q4	$1.65M	Buy	29,496 +6,676	+29%	+$362K	0.04%	224
2021 Q3	$1.1M	Buy	22,820 +13,932	+157%	+$674K	0.03%	267
2021 Q2	$372K	Buy	+8,888	New	+$345K	0.01%	570
2021 Q1	–	Sell	-572	Closed	-$20K	–	1130
2020 Q4	$20K	Buy	+572	New	+$19.8K	﹤0.01%	694
2020 Q3	–	Sell	-5,000	Closed	-$164K	–	937
2020 Q2	$164K	Sell	5,000 -4,940	-50%	-$158K	0.02%	182
2020 Q1	$300K	Buy	+9,940	New	+$296K	0.04%	131
2019 Q2	–	Sell	-700	Closed	-$18K	–	816
2019 Q1	$18K	Buy	+700	New	+$17.2K	﹤0.01%	440
2018 Q2	–	Sell	-440	Closed	-$11K	–	272
2018 Q1	$11K	Buy	+440	New	+$11.6K	0.01%	217
2017 Q3	–	Sell	-700	Closed	-$15K	–	290
2017 Q2	$15K	Hold	700	–	–	0.01%	293
2017 Q1	$12K	Buy	+700	New	+$12.2K	0.01%	271
2016 Q4	–	Sell	-1,000	Closed	-$21K	–	171
2016 Q3	$21K	Hold	1,000	–	–	0.02%	92
2016 Q2	$27K	Buy	+1,000	New	+$27.4K	0.03%	77

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pathstone Family Office's NVO Position: Q3 2023 in Review

Pathstone Family Office increased its Novo Nordisk (NVO) stake by 28% in Q3 2023, buying an estimated $997K and bringing the position to 51,058 shares worth $4.67M. The position accounts for 0.04% of the portfolio, ranked #286.

Pathstone Family Office first reported a position in NVO in Q2 2016 and has held it in 19 quarters since. The position peaked at $6.54M in Q4 2022. 1,307 funds tracked by Wall St. Rank hold NVO as of Q3 2023.

Pathstone Family Office held 51,058 shares of Novo Nordisk worth $4.67M as of Q3 2023.
Pathstone Family Office bought 11,320 Novo Nordisk shares in Q3 2023, an estimated $997K.
Novo Nordisk made up 0.04% of Pathstone Family Office's portfolio in Q3 2023, its #286 holding.
Pathstone Family Office first reported a position in Novo Nordisk in Q2 2016 and has held it in 19 quarters since.
Pathstone Family Office's Novo Nordisk position peaked at $6.54M in Q4 2022.
1,307 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.